APO-AMLODIPINE-ATORVASTATIN 80 MG
ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) : 80 MG AMLODIPINE (AMLODIPINE BESYLATE) : 5 MG · DIN 02411296 · APOTEX INC
Health Canada status: MARKETED
What is APO-AMLODIPINE-ATORVASTATIN?
APO-AMLODIPINE-ATORVASTATIN 80 MG contains ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) : 80 MG AMLODIPINE (AMLODIPINE BESYLATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02411296, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Nov-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-AMLODIPINE-ATORVASTATIN used for?
APO-AMLODIPINE-ATORVASTATIN is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate, specifically, patients at cardiovascular risk. APO-AMLODIPINE-ATORVASTATIN is not for initial therapy. The dose of APO-AMLODIPINE-ATORVASTATIN should be determined by the titration of individual components.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02411296 |
|---|---|
| Brand name | APO-AMLODIPINE-ATORVASTATIN |
| Generic / active ingredient | ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) : 80 MG AMLODIPINE (AMLODIPINE BESYLATE) : 5 MG |
| Manufacturer | APOTEX INC |
| Strength | 80 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10BX03 ATORVASTATIN AND AMLODIPINE |
| AHFS class | 24:06.08 ; 24:28.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Nov-2013 |
| Original market date | 2013-11-15 00:00:00 |
How is it stored and handled?
null
How is it supplied?
bottles of 100 tablets and blisters of 100 tablets (10x10) for 5/10 mg, 5/20 mg, 5/40 mg, 10/10 mg, 10/20 mg, 10/40 mg; bottles of 100 tablets and blisters of 50 tablets (5 x10) for 5/80 mg; bottles of 100 tablets and blisters of 50 tablets (5x10) for 10/80 mg
Is ATORVASTATIN AND AMLODIPINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10BX03 ATORVASTATIN AND AMLODIPINE. 24 of 40 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-AMLODIPINE-ATORVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02411326 |
| APO-AMLODIPINE-ATORVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02411342 |
| APO-AMLODIPINE-ATORVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02411318 |
| APO-AMLODIPINE-ATORVASTATIN | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02411334 |
| APO-AMLODIPINE-ATORVASTATIN | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02411288 |
| APO-AMLODIPINE-ATORVASTATIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02411253 |
| APO-AMLODIPINE-ATORVASTATIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02411261 |
| CADUET | 10 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02273306 |
| CADUET | 10 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02273292 |
| CADUET | 10 MG | TABLET | BGP PHARMA ULC | MARKETED | DIN 02273284 |
Who else supplies ATORVASTATIN AND AMLODIPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATORVASTATIN AND AMLODIPINE appears in 2136 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.